|  Sign up!  


Return to Course Listing



CME: Major Depressive Disorders (MDD): Best Practice And The Role Of Novel Therapies


Program Description / Statement of Need:

In this online CME self-learning program:


Major depressive disorder (MDD) is presently and has been a persistent major public health burden for several decades.1-5 Based on the National Comorbidity Survey data using the Composite International Diagnostic Interview, the estimated risk of MDD over any given 12-month period is 6.6% (13.1 – 14.2 million U.S. adults), with an estimated lifetime risk of 16.2% (32.6 – 35.1 millions US adults).1,2 Another estimate, from a recent wave of the National Health and Nutrition Examination Survey, indicates that 17.53% of men and 25.52% of women across all ages report having experienced depressive symptoms in the past.4 Unfortunately, 58.8% of adults with symptoms classified as moderate and 36.9% of adults with symptoms classified as severe neither saw mental health professional nor received pharmacological treatment,4 suggesting a gap between present and optimal treatment of MDD.


This program has been designed to bring healthcare professionals’ knowledge up to date with the currently best and recommended practices in treating MDD.





Introduction, disclosures

Epidemiology and risk factors for major depressive disorder

  • •Statistics: snapshots and trends
  • •Pathogenesis: altered neurotransmitter levels (serotonin, dopamine, and norepinephrine)
  • •Family history and physical illness
  • •Genetic factors

Symptomology and diagnosis of MDD [Learning objective #s 1, 2, & 3]

  • •Presence of depressed mood, anhedonia, and/or associated symptoms
  • •Differential diagnosis; exclusion of other causes (e.g., medical causes and/or substance use, bereavement, bipolar disorder).
  • •Biomarkers
  • •Patient case(s)

Treatment in patients with MDD [Learning objective #s 3, 4, & 5]

  • •Therapies depending on disease severity and presentation: pharmacologic vs. non-pharm, first-line and beyond [Objective #3]
  • •Continuation / maintenance therapy, prevention of relapse, and change in agent(s) [Objective #4]
  • •Newer pharmacotherapies and medical device treatment and their role in clinical practice [Objective #5]
  • •Clinical conundrums: treatment-refractory MDD
  • •Best practice: put it all together
  • •Patient cases [Objectives #3,4,5]

Barrier to Optimal Care in Patients with Major Depressive Disorder [Objective #6]

  • •Provider-patient relationship
  • •Adherence and patient perception

Summary, conclusion, and best practice recap


Target Audience:

Healthcare professionals specializing in: psychiatry, primary care, and those who otherwise commonly care for patients with MDD or related psychiatric diseases.

Program Objectives:

By the end of the session the participant will be able to:

    • Recognize and provide optimal care for patients with MDD including regular assessment of symptom resolution, treatment adherence, and tolerability concerns.
    • Describe the impact of acute and residual symptoms of cognitive dysfunction in depression on patient function, quality of life, relapse risk and long-term outcomes
    • Identify patients who might benefit from new pharmacologic treatment options (e.g., those with inadequate response to therapy or tolerability concerns).
    • Effectively and safely integrate care changes into the MDD treatment regimen as needed to achieve long-term treatment success.
    • Identify newer pharmacotherapies and medical device treatment MDD and contrast them with therapies to determine their place.


    This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.


    Credit Designation: ScientiaCME designates this educational activity for a maximum of  1.0 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.




    ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmaceutical education. This program is approved for 1.0 hours (0.1 CEUs) of continuing education.  Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test.   Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.  ACPE # 0574-0000-16-002-H01-P.  ACPE Accreditation effective 4/13/2016, expires 4/13/2018. 

    This is a Knowledge (K)-type activity.

    Release Date: April 12, 2016
    Expiration Date: April 12, 2018

    Faculty: Charles DeBattista MD

    Faculty Disclosure and Resolution of COI:

     As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.


    Faculty Disclosure:


    Charles De Battista, MD discloses that he has received grant funding and / or is a consultant for Genentech, Pfizer, Assurex, Brain Resources, and St. Jude.

    Disclosures of Educational Planners: Charles Turck, PharmD is an officer and part owner of ScientiaCME, LLC with no relevent financial disclosures.


    Commercial Support Disclosure: This program is supported by an educational grant from Alkermes.

    Additional Courses That Are Related To This Course

    Best Practices and Advances in Treatment Strategies in Bipolar Disorder Pharmacotherapy

    Alcohol Use Disorder (AUD): Therapeutic Updates and Best Practices

    Major Depressive Disorder (MDD): Updates from the American Psychiatric Association Annual Meeting (APA) 2017

    Schizophrenia: Updates from the American Psychiatric Association Annual Meeting (APA) 2017


    Viewing Instructions



    Windows 2000 or above
    Internet Explorer 5.5
    Adobe Acrobat Reader*

    Mac OS 10.2.8
    Adobe Acrobat Reader*
    Internet Explorer is not supported on the Macintosh


    *Required to view Printable PDF Version


    Privacy Policy



    -Read the learning objectives and faculty disclosures above

    -Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowedge gained by participating in this CME activity.

    -View the on-line program. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.

    -Take the post-test

    -Complete the program evaluation and CME registration. A CE certificate will be emailed to you.

    Perform Pre-Test (optional)
    Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.

    Download the Presentation (optional)


    View the online program


    Perform Post-Test

    Complete the Symposium Evaluation and Request CE Certificate

This program is supported by an educational grant from Alkermes.


Your feedback is important to us. Please Contact Us to let us know how to make this site better. Thank you.